News

Walgreens shares jumped Tuesday after a report the pharmacy chain's possible deal to sell itself to private equity firm Sycamore Partners may be back on the table.

Mexico's Economy Secretary Marcelo Ebrard said Tuesday that he will meet with Trump administration officials in Washington on Thursday in what he called “the first conversation” in a series of negotiations between the two countries. The meeting comes at a fragile moment for the two neighbors, whose bilateral trade exceeded $800 billion last year. U.S. President Donald Trump has threatened to impose 25% tariffs on all imports from Mexico — though so far limited them to steel and aluminum — and signed an executive order to rename the Gulf of Mexico as the Gulf of America.

Elon Musk's controversial role in the Trump administration appears to be dragging down the Tesla CEO's image — and brand — during a pivotal time for the EV industry.

Shares of beer, wine, and spirits company Constellation Brands (NYSE:STZ) jumped 8.7% in the pre-market session after Warren Buffett's Berkshire Hathaway revealed a position in the company (STZ) worth roughly $1.2 billion in the fourth quarter of 2024. Given Buffett's reputation for identifying quality opportunities in the stock market, the market is likely to read the information positively for the company's prospects in the near term.

Shares of pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA) jumped 13.5% in the morning session after CNBC's David Faber said that a potential deal between the company (Walgreens) and private equity firm Sycamore Partners "was showing signs of life." The stock's reaction is lifting investors' optimism as markets continue to digest the long-term implications of its recent dividend suspension (first time in over 90 years) and lawsuit with the Department of Justice.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results. Despite this, Barclays seems to be exercising caution, downgrading the stock to equal weight from overweight earlier in the morning. The firm cited "policy risks, fewer clinical catalysts, and broader economic uncertainties that could limit its upside.".

Shares of packaged foods company Conagra Brands (NYSE:CAG) fell 7.7% in the morning session after the company reported underwhelming preliminary full-year 2025 guidance and expects sales and profits to be below its previous forecast. Precisely, the company expects full-year earnings of about $2.35 (vs. previous guidance of $2.45 to $2.50 per share). Organic sales are also expected to decline by 2% year on year (vs previous guidance of a decline between 1.5% and flat growth).